Skip to main content
Download PDF

Fitness costs of Tn1546-type transposons harboring the vanA operon by plasmid type and structural diversity in Enterococcus faecium

Annals of Clinical Microbiology and Antimicrobials volume 23, Article number: 62 (2024) Cite this article

Abstract

Background

This study analyzed the genetic traits and fitness costs of vancomycin-resistant Enterococcus faecium (VREfm) blood isolates carrying Tn1546-type transposons harboring the vanA operon.

Methods

All E. faecium blood isolates were collected from eight general hospitals in South Korea during one-year study period. Antimicrobial susceptibility testing and vanA and vanB PCR were performed. Growth rates of E. faecium isolates were determined. The vanA-positive isolates were subjected to whole genome sequencing and conjugation experiments.

Results

Among 308 E. faecium isolates, 132 (42.9%) were positive for vanA. All Tn1546-type transposons harboring the vanA operon located on the plasmids, but on the chromosome in seven isolates. The plasmids harboring the vanA operon were grouped into four types; two types of circular, nonconjugative plasmids (Type A, n = 50; Type B, n = 46), and two types of putative linear, conjugative plasmids (Type C, n = 16; Type D, n = 5). Growth rates of vanA-positive E. faecium isolates were significantly lower than those of vanA-negative isolates (P < 0.001), and reduction in growth rate under vancomycin pressure was significantly larger in isolates harboring putative linear plasmids than in those harboring circular plasmids (P = 0.020).

Conclusions

The possession of vanA operon was costly to bacterial hosts in antimicrobial-free environment, which provide evidence for the importance of reducing vancomycin pressure for prevention of VREfm dissemination. Fitness burden to bacterial hosts was varied by type and size of the vanA operon-harboring plasmid.

Background

Enterococci have emerged as one of the leading causes of hospital-associated bacterial infections due to both intrinsic and acquired resistance against many groups of antimicrobials and tolerance to stresses such as disinfectants. Enterococcus faecalis caused three-fourths of cases of enterococcal infection in humans in the late 1990s [1]. However, it has repeatedly been reported in recent years that Enterococcus faecium exceeds E. faecalis in prevalence of human infections, which might be due to rapid adaptation of E. faecium to nosocomial conditions by acquiring resistance against anti-enterococcal antimicrobials, including ampicillin, high-level aminoglycosides, and glycopeptides [2]. Furthermore, resistance to glycopeptides in E. faecium has been shown to be an important risk factor for an increased early mortality rate and prolonged hospital stays in patients with bloodstream infections [3, 4].

The most common mechanism of resistance against glycopeptides in E. faecium is acquisition of an operon harboring van genes. Among the nine van genotypes, vanA (80–90%) and vanB (10–20%) have been predominantly identified in vancomycin-resistant E. faecium (VREfm), though the proportion of vanA and vanB genes varies geographically [5, 6]. The vanA operon is composed of regulatory genes (vanR and vanS), genes for peptidoglycan modification enzymes (vanH, vanA, and vanX), and accessory genes (vanY and vanZ) as a part of Tn1546-type transposons located on plasmids [7]. The vanB operon includes genes homologous with the vanA operon, except that the vanW gene instead of vanZ is present [8], and it has been commonly identified in Tn1549 or Tn5382 on the bacterial chromosome [9, 10].

VREfm of sequence type 17 (ST17) harboring a plasmid with resistance determinant against glycopeptide (VR-plasmid) carrying the vanA operon, has been identified as a major clone showing global dissemination; however, regional distribution of VREfm among diverse STs by country or region and shifts in predominating clones over time by emerging successful clones have also been identified. In Australia, exchange of the dominant vanB-ST796 VREfm clone by vanA-ST1421 has been observed since 2016 [11, 12]. In Germany, rapid dissemination of the vanB-ST117 VREfm clone resulted in an inversion in prevalence between vanA and vanB (from 2:1 to 1:3) in 2019 [13]. In South Korea, vanA-ST17 was the predominating VREfm clone since its emergence in the 1990s, but dissemination of emerging vanA-ST1421 has recently been reported [14].

Shifts in clonal distribution of VREfm might be affected by multiple factors, including environmental factors such as infection control strategies, antimicrobial pressure, and microbial factors including fitness costs of resistance determinants to bacterial hosts [15, 16]. The fitness cost of acquisition of a plasmid may vary according to the size and replicon type, number and mechanism of resistant alleles, and traits of bacterial hosts [15]; interactions between a plasmid and a bacterial host may also play an important role in determining the cost [16]. In general, possession of a plasmid with resistance determinant may be costly, though it could be nearly cost-free or even beneficial to the bacterial host in some cases [17, 18]. Although fitness costs may be an important factor for emerging successful multidrug-resistant clones, studies on epidemic clones of VREfm are still scarce.

This study was performed to determine the genetic traits of successful VREfm clones in South Korea and their plasmids harboring the vanA operon. Determination of the growth dynamics of VREfm blood isolates was also performed to measure the fitness costs of vanA operon-containing plasmids for bacterial hosts, which might have an effect on shifts in the clonal distribution of VREfm strains.

Methods

Study design

All patients with E. faecium bloodstream infection (BSI) between January and December 2019 in eight general hospitals participating in the Global Antimicrobial Surveillance System in South Korea, Kor-GLASS, were included in this study [2]. Clinical information, including demographic conditions, underlying comorbidities, and antimicrobial treatment regimens, was investigated. Hospital-originated infection was defined when an initial blood culture was performed after ≥ 2 calendar days of hospitalization. The Charlson comorbidity index and Sepsis-related Organ Failure Assessment (SOFA) score were calculated as previously described [19, 20]. Clinical outcomes included 30-day mortality, 60-day mortality, and in-hospital mortality. The first E. faecium blood isolate from each patient was collected for microbiological studies, and duplicate isolates were discarded.

Microbiological assessment

Bacterial species were identified using a Bruker Biotyper (Bruker Daltonics, Bremen, Germany) and confirmed by 16S rRNA sequencing. Antimicrobial susceptibility against ampicillin, ciprofloxacin, tetracycline, and quinupristin/dalfopristin was determined by the disk diffusion method. The minimum inhibitory concentrations (MICs) of vancomycin, teicoplanin, linezolid, gentamicin, and streptomycin were determined using the broth microdilution method. Interpretation of zone diameter and MICs were followed the clinical breakpoints of CLSI guideline [21]. vanA and vanB gene carriage was evaluated by PCR for all E. faecium isolates [22, 23].

Whole-genome sequencing

Genomic DNA was extracted from 132 vanA-positive E. faecium isolates with a GenElute bacterial genomic DNA kit (Sigma‒Aldrich, St. Louis, MO). Libraries were prepared using SMRTbell Express Template Prep Kit 2.0 (Pacific Biosciences of California, Menlo Park, CA). Entire genomes were sequenced using SMRT cell 1 M by the PacBio Sequel II system (Pacific Biosciences of California). Genome assemblies were performed using PBMM2 (https://github.com/PacificBiosciences/pbmm2; last updated in June 2021), and annotation of the assembled contigs was performed using PROKKA [24].

Strain typing and phylogenetic analysis

Multilocus sequence typing (MLST) was performed by determining the allelic types of seven housekeeping genes, as previously described [25]. Core genome MLST (cgMLST) was determined by analyzing 1423 loci with the E. faecium cgMLST scheme v.1.1 using SeqSphere v.9.0.1 (Ridom GmbH, Munster, Germany) [26]. A cgMLST-based minimum spanning tree was generated with genomic sequences covering > 90% of target loci.

In silico molecular analysis

Antimicrobial resistance determinants were identified by ResFinder (https://cge.food.dtu.dk/services/ResFinder/) [27], and replicons of plasmids were identified by PlasmidFinder (https://cge.food.dtu.dk/services/PlasmidFinder/) [28]. The bacterial type II toxin-antitoxin system was assessed by comparison with the TADB 2.0 database [29]. NCBI Basic Local Alignment Search Tool was used to compare the structure of plasmids, and plasmid maps were generated using the Proksee online tool (https://proksee.ca/).

Conjugation

Broth mating was performed to estimate the plasmid transfer frequency of vanA operon-harboring plasmids in E. faecium isolates using E. faecium DSM13589 as a recipient. Mixtures of equal amounts of donor and recipient bacterial cells were incubated in Mueller–Hinton (MH) broth (Difco Laboratories, Detroit, MI) and spread on MH agar (Difco Laboratories) containing fusidic acid (20 mg/L), rifampicin (30 mg/L), and vancomycin (4 mg/L). Putative transconjugant cells were confirmed by antimicrobial susceptibility phenotype and possession of vanA, and the conjugation efficiency was calculated per both the number of donor cells and recipient cells.

Bacterial growth rate

Growth rates of the E. faecium isolates were determined by measuring optical density at 600 nm (OD600) using a Multiscan spectrophotometer (Thermo Fisher, Waltham, MA). Bacterial colonies were incubated overnight in Luria–Bertani broth (Difco Laboratories) at 37 °C with shaking, and diluted bacterial suspensions were incubated in MH broth while measuring OD600 every 3 min. Growth rates of VREfm isolates under both 4 mg/L and 16 mg/L concentrations of vancomycin in MH broth were also determined. Each measurement was replicated three times in the same run, and three independent runs were performed. The average of the maximum slope values of lnOD600 over time was calculated as the growth rate of the bacterial isolates.

Statistical analysis

Statistical analyses were performed using R software version 4.3.1 (R development Core Team 2023; http://www.R-project.org/), and the results with P value < 0.05 were considered to be significant. Differences between two groups were analyzed using the Mann‒Whitney U test and Fisher’s exact test for continuous variables and categorical variables, respectively. Kruskal–Wallis tests were conducted to determine differences among more than three groups, and significant results were further analyzed using post hoc Dunn’s tests with Bonferroni correction for pairwise comparisons to identify specific groups with significant differences. A Kaplan‒Meier curve was constructed, and the log-rank test was performed. Packages ‘ggpubr’ and ‘ggsurvplot’ were used for visualization of the statistical analysis results.

Results

Characteristics of the patients with E. faecium BSI

During the one-year study period, blood culture was performed for 87,399 patients with suspected BSI in eight sentinel hospitals, and 10,990 (12.6%) were positive for at least one bacterial or fungal pathogen. Among them, 308 cases (2.8% of positive blood culture) of E. faecium BSI were identified and included in this study (Table 1). The median age of the patients was 72.5 years, ranging from 61 to 80 years, and more than half (54.9%, 169/308) were male. Most patients were inpatients in general wards (51.6%, n = 159) and intensive care units (37.0%, n = 114); only 11.4% (n = 35) of them were outpatients. Almost four-fifths (77.9%, n = 240) of cases were hospital-originated infections. The most common underlying comorbidities were malignancies (28.2%, n = 87), followed by diabetes mellitus (16.9%, n = 52) and cardiovascular diseases (16.2%, n = 50).

Table 1 Characteristics of the patients with BSI and causative E. faecium pathogens
Full size table

Antimicrobial resistance phenotypes of E. faecium blood isolates

Among the 308 E. faecium blood isolates, 132 (42.9%) showed positive results in vanA PCR, with none being positive in vanB PCR. All vanA-positive isolates were resistant to ampicillin and ciprofloxacin. High-level resistance to gentamicin was also identified in 39.4% (52/132) of the isolates, but none of them showed high-level resistance to streptomycin. Three-quarters of the isolates (75.0%, 99/132) exhibited VanA phenotypes, i.e., high-level resistance to vancomycin (MIC, > 64 mg/L) and resistance to teicoplanin (MIC, ≥ 32 mg/L); 29 (22.0%) isolates exhibited VanD phenotypes, i.e., high-level resistance to vancomycin (MIC, > 64 mg/L) and intermediate resistance (n = 22; MIC = 16 mg/L) or reduced susceptibility (n = 7; MIC = 8 mg/L) to teicoplanin. The remaining four (3.0%) isolates were susceptible to both vancomycin (MIC, 0.5–1 mg/L) and teicoplanin (MIC, 0.12–0.25 mg/L), indicating vanA-positive but vancomycin-susceptible (vanA+VS) phenotypes.

Clinical outcome of patients with E. faecium BSI

Compared to those caused by vanA-negative E. faecium, BSIs caused by vanA-positive E. faecium occurred more frequently in inpatients (95.5% versus 85.2%; P value = 0.006) and in patients with a higher SOFA score (median value, 7.0 versus 4.0; P value = 0.001). The 30-day mortality rate was higher in patients with vanA-positive E. faecium BSI than in those with vanA-negative E. faecium BSI, but without statistical significance (36.4% versus 27.3%, P = 0.114). However, both the 60-day mortality (46.2% versus 30.1%; P value = 0.005) and in-hospital mortality (54.5% versus 33.5%; P value < 0.001) were significantly higher in vanA-positive E. faecium BSI patients than in vanA-negative E. faecium BSI patients (Figure S1).

Genetic characteristics of vanA-positive E. faecium blood isolates

Circularized chromosomes were obtained from 120/132 vanA-positive E. faecium isolates by whole-genome sequencing, and mean value of coverage depth was 267.3 ranging from 92 to 620. Median size of circularized chromosomes was found to be 2,881,288 bp, ranging from 2,446,701 bp to 3,003,360 bp. The isolates carried one to three plasmids, with Rep A_N family and Inc18 family plasmids most frequently being identified. The most common strain type of vanA-positive blood isolate was ST1421 (n = 52), followed by ST17 (n = 36), ST80 (n = 15), ST192 (n = 12), and ST252 (n = 5) (Fig. 1). By cgMLST, 37 different complex types (CTs) were identified, and CT6141-ST17 (n = 23) was the most common, followed by CT6552-ST1421 (n = 20), CT6555-ST1421 (n = 15), and CT6554-ST192 (n = 10). One (n = 123) or two (n = 9) copies of the vanA operon were identified in each isolate, regardless of its location on a plasmid (n = 127) and/or the chromosome (n = 7); 2/132 isolates carried the vanA operon both on the chromosome and on a plasmid. Other resistance genes frequently identified on chromosomes were aminoglycoside-modifying enzyme-encoding genes aac(6’)-Ii (97.7%, n = 129) and ant(9)-Ia (60.6%, n = 80) and macrolide resistance-related genes msr(c) (97.7%, n = 129) and erm(A) (62.9%, n = 83).

Fig. 1
figure 1

Phylogenetic tree based on cgMLST of vanA-positive E. faecium isolates

Full size image

Structure of Tn1546-type transposons and glycopeptide resistance phenotypes

vanA operons were identified as a part of Tn1546-type transposons, and 128 blood isolates exhibiting a VanA or VanD phenotype carried one (n = 119) or two (n = 9) copies of the transposon classified as six structural variants both by deletion or truncation of vanY and vanZ and by insertion of ISEfa11 between vanX and IS1216 (Fig. 2A). The vanS gene of all 128 isolates showed nucleotide sequence variations resulting in three amino acid substitutions, L50V, E54Q, and Q69H, compared with the vanS gene of pIP501 [7, 30]. The remaining four isolates with vanA+VS phenotypes were found to carry a structurally impaired vanA operon, either lacking one or both regulatory genes vanR and vanS or having a truncated D-alanyl-D-alanine dipeptidase gene vanX, on a plasmid.

Fig. 2
figure 2

Structure of Tn1546-type transposons and teicoplanin MICs of E. faecium hosts according to the structure of vanY. Blue bars in the bar graph (C) indicate the clinical breakpoints according to the CLSI guideline, and red one indicates those according to the EUCAST

Full size image

The 128 isolates with the VanA or VanD phenotype were grouped according to the vanA operon copy number and structure. Group 1 isolates (n = 24) showing the typical VanA phenotype carried a plasmid harboring a copy of a Tn1546-type transposon (Tn1546vanRSHAXYZ) with all seven component genes of the vanA operon, with (variant Ib, n = 2) or without (variant Ia, n = 22) insertion of ISEfa11. Group 2 isolates (n = 89) carried a copy of the Tn1546 variant with both truncation of vanY and deletion of vanZ by insertion of an IS1216 into vanY (Tn1546vanY::IS1216,ΔvanZ) with (variant IIb, n = 45) or without (variant IIa, n = 44) insertion of ISEfa11. The isolates exhibited VanA or VanD phenotype, and the Tn1546vanY::IS1216,ΔvanZ variants were found to be located either on a plasmid (n = 85) or on the chromosome (n = 4). The length of remnant vanY in Tn1546vanY::IS1216,ΔvanZ varied from 165 to 901 bp according to the insertion site, which did not show any correlation with teicoplanin MICs. Group 3 isolates (n = 6) exhibiting the VanD phenotype carried a copy of the Tn1546-type transposon with deletion of both vanY and vanZ [Tn1546Δ(vanY-vanZ)] with (variant IIIb, n = 2) or without (variant IIIa, n = 4) insertion of ISEfa11 on a plasmid. Nine isolates harbored two copies of Tn1546-type transposons on a plasmid and/or on the chromosome (Fig. 2B). Of them, five and one isolates exhibiting the VanA phenotype possessed one each copy of Tn1546vanRSHAXYZ and Tn1546Δ(vanY-vanZ) and Tn1546vanY::IS1216,ΔvanZ and Tn1546Δ(vanY-vanZ), respectively. The remaining three isolates carried two copies of Tn1546vanY::IS1216,ΔvanZ and showed the VanA (n = 2) or VanD (n = 1) phenotype (Fig. 2B).

Chromosomal vanA operon

One (n = 6) or two (n = 1) copies of the vanA operon were identified on the chromosome in seven isolates of CT6555-ST1421 (n = 4), CT6141-ST1421 (n = 1), CT6552-ST1421 (n = 1), and CT6557-ST78) (n = 1), and two of them carried an additional vanA operon-harboring plasmid (Fig. 3). The vanA operons found on the chromosome were always identified in an insertion unit with (n = 6) or without (n = 2) plasmid-originated components, resulting in variable sizes of the units, ranging from 9 to 43 kb. All eight insertion units were shown to be flanked by a pair of IS1216 of the same or opposite orientations and left (5'-GGT TCT GTT GCA AAG TTT TAA ATC TAC TAT CAA ATA AGG TAG AAT AG-3') and right (5'- GGT TCT GTT GCA AAG TTT TAA ATA AAG AAT AAA ATC CTT ACG GTA TCT AT-3') inverted repeats. The insertion events on the chromosome were shown to be neither site-specific nor nucleotide sequence-specific, occurring in coding regions (n = 5) or in intergenic regions (n = 3). Of note, both isolates C0019EM0016 and C0019EM0037 of CT6555-ST1421 recovered in a hospital with a 7-month gap shared an insertion unit at the same location on the chromosome, indicating a clone; however, the isolate C0019EM0037 carried another insertion unit at a different location on the chromosome, suggesting that another independent insertion event occurred.

Fig. 3
figure 3

Structure and location of the chromosomal vanA operon. The red bars in chromosome indicate the insertion sites of Tn1546-type transposon. Red arrows indicate the genes identified as resistance determinants, and blue arrows indicate the insertion sequences

Full size image

VR-plasmids harboring the vanA operon

A total of 127 VR-plasmids carrying one (n = 122) or two (n = 5) copies of Tn1546-type transposons were identified. Circular plasmids of the Inc18 family (n = 96) were most common, followed by putative linear plasmids of the RepB family (n = 21); a circular plasmid of hybrid Inc18:RepA_N was also identified. The remaining nine plasmids were nontypeable due to failure in plasmid circularization (n = 5) or in identification (n = 4) of the plasmid replication origin.

All circular plasmids of the Inc18 family were found to share 14–15 kb-sized derivatives from the plasmid pRE25, including a rep2 replication origin, the erm(B) gene, and a zeta-epsilon toxin-antitoxin system, but to lack the probable conjugation regions (ORF25 to ORF39 of pRE25) [31], compatible with the unsuccessful results in conjugation experiments for all E. faecium isolates carrying the plasmids. The 96 circular plasmids were divided into types A (n = 50) and B (n = 46) according to both sequence similarity (> 60%) and Tn1546 variant type (Fig. 4A and B). Type A plasmids had a median size of 32,082 bp, ranging from 18,701 bp to 43,334 bp, and were most frequently identified in E. faecium isolates of ST17 (46%, 23/50). Type A plasmids possessed either Tn1546 variant IIa (n = 45) or variant IIIa (n = 3), except for two plasmids harboring a Tn1546-type transposon with a structurally impaired vanA operon, both identified in vanA+VS isolates (Table 2). Type B plasmids had a median size of 42,610 bp, ranging from 27,214 bp to 51,084 bp, and were mostly (80.4%, 37/46) identified in E. faecium isolates of ST1421. Tn1546 variants identified in type B plasmids always showed insertion of ISEfa11 between vanX and IS1216, and variant IIb (n = 41) was most common, followed by variant Ib (n = 3) and variant IIIb (n = 2). Most (97.8%, 45/46) type B plasmids also had an aminoglycoside resistance determinant aph(3')-IIIa.

Fig. 4
figure 4

Structure of four types of plasmids containing Tn1546-type transposons

Full size image
Table 2 Characteristics of plasmids harboring the vanA operon
Full size table

A putative replication origin of the RepB family was found in 21 putative linear plasmids with either one (type C, n = 16) or two (type D, n = 5) hairpin ends composed of inverted tandem repeat sequences of 2 kb with 5'-TATA-3' hairpin loops (Fig. 4C and D). The plasmids exhibited homology of approximately 70% with the linear plasmid pELF1 [32], and they shared putative transfer-related components ftsK and parA. More than half (57.1%, 12/21, 10 type C and two type D) of the plasmids were successfully conjugated to the recipient E. faecium DSM13589. The type C plasmids had a median size of 106,938 bp, ranging from 72,306 to 112,181 bp. The single hairpin end of the plasmids were observed to harbor a copy of Tn1546vanRSHAXYZ (14/16), Tn1546Δ(vanY-vanZ) (n = 1), or a Tn1546-type transposon with a structurally impaired vanA operon (n = 1); other resistance determinants ant(9)-Ia (n = 6) and erm(A) (n = 5) were also identified at the opposite end of the plasmids. The type D plasmids had a median size of 118,791 bp, ranging from 102,459 to 161,239 bp, and harbored two copies of the Tn1546-type transposon, each copy of Tn1546vanRSHAXYZ and Tn1546Δ(vanY-vanZ) at each hairpin end. The plasmids also harbored the resistance determinants erm(B) and aph(3')-IIIa.

Bacterial growth rate

The median growth rate [Max(∆lnOD600/s)] of vanA-negative ampicillin-resistant E. faecium blood isolates in MH broth was 0.195 (1st to 3rd interquartile range, 0.178 to 0.211), which was significantly higher than that of vanA-positive ampicillin-resistant isolates (median value, 0.178; 1st to 3rd interquartile range, 0.162 to 0.191; P < 0.001) (Fig. 5A).

Fig. 5
figure 5

Bacterial growth rates of E. faecium blood isolates. *** indicate P value < 0.001

Full size image

The growth rates of four vanA+VS isolates (median value, 0.200; range, 0.156 to 0.220) were similar to those of vanA-negative isolates. Growth rates of vanA-positive isolates did not differ by strain type or R plasmid type carrying the vanA operon (Fig. 5B and C). Addition of vancomycin at concentrations of 4 mg/L and 16 mg/L to MH broth resulted in a significant decrease in the growth rates of vanA-positive E. faecium isolates, regardless of plasmid type (Fig. 5D–F). Notably, the growth rates of ST1421 and ST17 vanA-positive E. faecium isolates at a vancomycin concentration of 4 mg/L (median value, 0.154; 1st to 3rd interquartile range, 0.139–0.166) were significantly faster than those of vanA-positive isolates of other STs (median value, 0.143; 1st to 3rd interquartile range, 0.122–0.160; Fig. 5G). The difference between growth rates in MH broth without vancomycin and with vancomycin at a concentration of 4 mg/L was significantly lower for isolates carrying a type A or B circular plasmid than those carrying a type C or D linear plasmid (Fig. 5H; P = 0.020).

Discussion

Our experiments revealed a significant difference in growth rates between vanA-positive and vanA-negative E. faecium blood isolates in MH broth, suggesting that it is costly to bacterial hosts in antimicrobial-free environments to carry the vanA operon, regardless of the location of the operon on a plasmid or the chromosome. This fitness burden might be attributed to the basal expression level of the vanA gene even in antimicrobial-free environments [33]. The growth rates of four vanA+VS isolates with a structurally impaired vanA operon were similar to those of vanA-negative isolates in our study, though a statistically significant difference with those of VREfm isolates was not observed due to the small number of cases. Complete inactivation of the vanA operon in vanA+VS isolates might be a way to overcome the fitness burden for vanA-carrying E. faecium bacterial hosts when exposed to antimicrobial-free environments [34]. These findings provide evidence for the importance of reducing vancomycin pressure through antimicrobial stewardship in clinical fields to prevent dissemination of VREfm.

Addition of vancomycin at a sub-MIC concentration of 4 mg/L to MH broth significantly slowed the growth rates of VREfm isolates compared with those in MH broth without antimicrobials. Both increased fitness burden to bacterial hosts by increased expression level of the vanA gene and growth inhibition effects of vancomycin might affect the growth rates of VREfm isolates [35]. It is noteworthy that the difference in growth rate was significantly larger in isolates carrying a type C or D putative linear conjugative plasmid (approximately 100–200 kb) than in those carrying a type A or B circular nonconjugative plasmid (approximately 30–40 kb), indicating that the former plasmids are costlier to bacterial hosts under vancomycin pressure. Furthermore, both predominant VREfm clones of ST1421 and ST17, which mostly harbored a type A or B plasmid, exhibited significantly faster growth rates in MH broth with vancomycin than other VREfm isolates. These findings evidence the reason for the success of predominant VREfm clones in hospital settings under persistent vancomycin pressure. However, significant difference was not identified in the subgroup analyses with 32 ST17 strains including 26 with circular plasmids and 6 with putative plasmids due to the limited number of strains belonging to same ST. Further investigation about fitness cost according to the bacterial hosts and their plasmid type should be performed.

Bacterial hosts might possess a nonconjugative plasmid harboring the Tn1546-type transposon in two possible ways: (1) loss of essential components for conjugation on the plasmid by genetic recombination events after acquisition of the plasmid by conjugation [36, 37] and (2) intracellular mobilization of the Tn1546-type transposon from a conjugative plasmid to a nonconjugative plasmid [38]. In our study, most of the type A and B nonconjugative plasmids harbored Tn1546vanY::IS1216,ΔvanZ, whereas most of the type C and D conjugative plasmids harbored Tn1546vanRSHAXYZ. Tn1546-type transposons were always found to be bracketed by IS1216 elements, and both truncation of vanY and deletion of vanZ in types A and B plasmids might result from insertion of IS1216 at the random sequences of vanY of Tn1546vanRSHAXYZ, leaving variable sizes of vanY remnants. Furthermore, the EFM isolate G0019EM0008 co-carried a type C plasmid harboring Tn1546vanRSHAXYZ with an additional pRE25-like plasmid, sharing a backbone structure with type A plasmids but lacking Tn1546, which might constitute a snapshot before an intracellular mobilization event of the transposon.

Tn1546-type transposons were also identified on the chromosomes of seven VREfm isolates with or without surrounding components of type B circular plasmids, suggesting the origin of the transposons. Insertion of plasmid-originated antimicrobial resistance determinants into the chromosome has also been reported for other bacterial species, such as ISEcp1-blaCTX-M in Escherichia coli and Salmonella species, and ISAba1-blaOXA-23 in Acinetobacter baumannii [39,40,41]. This phenomenon might indicate an internalization process of antimicrobial resistance determinants by bacterial hosts in response to constant antimicrobial pressure. Notably, most VREfm isolates harboring the Tn1546-type transposon on their chromosome were shown to belong to ST1421. The ST1421 VREfm isolates, which were first identified in Australia, had a large chromosomal inversion resulting in deletion of 3.5- to 8.7-kb chromosomal sequences, including the pstS gene [42]. The high genome plasticity of this notorious clone might be a preferred condition for insertion of the Tn1546-type transposons on the chromosome.

Tn1546vanY::IS1216,ΔvanZ was found to confer variable levels of resistance against teicoplanin to bacterial hosts, from reduced susceptibility (MIC = 8 mg/L) to high-level resistance (MIC ≥ 32 mg/L), but Tn1546vanRSHAXYZ conferred high-level resistance, consistent with previous reports [43, 44]. However, identical nucleotide sequence variations in vanS were identified in all VREfm isolates regardless of their susceptibility phenotype to teicoplanin, inconsistent with a previous report [30], indicating that they might not cause functional changes in VanS protein capability.

A limitation of this study is that the VREfm isolates were collected in a single country, South Korea, and the local distribution of the strain type of VREfm isolates, type of plasmids carrying the Tn1546-type transposon, and structure of the Tn1546-type transposon might be reflected in the results of this study. Another limitation is that the growth rate of E. faecium blood isolates were determined at nutrient-rich conditions, therefore, further investigation including competitive growth and in vivo adaptation experiments and should be performed to clarify the effects of fitness costs.

Conclusions

The possession of Tn1546-type transposon harboring vanA operon was costly to bacterial hosts in antimicrobial-free environment, which provide evidence for the importance of reducing vancomycin pressure for prevention of VREfm dissemination through antimicrobial stewardship in clinical fields. Fitness burden to bacterial hosts of Tn1546-type transposon was varied by type and size of the vanA operon-harboring plasmid, which could have an impact on successful dissemination of the epidemic clones.

Availability of data and materials

The genome data of this study are available from National Centers for Bio Informatics in BioProject under accession PRJNA983092.

Abbreviations

VREfm:

Vancomycin-resistant Enterococcus faecium

VR-plasmid:

Plasmid with resistance determinants against vancomycin

BSI:

Bloodstream infection

SOFA:

Sepsis-related Organ Failure Assessment

MIC:

Minimum inhibitory concentration

MLST:

Multilocus sequence typing

cgMLST:

Core genome multilocus sequence typing

MH:

Mueller–Hinton

OD600 :

Optical density at 600 nm

References

  1. Chong Y, Lee K, Park YJ, Jeon DS, Lee MH, Kim MY, et al. Korean nationwide surveillance of antimicrobial resistance of bacteria in 1997. Yonsei Med J. 1998;39:569–77.

    Article  CAS  PubMed  Google Scholar 

  2. Kim D, Yoon EJ, Hong JS, Choi MH, Kim HS, Kim YR, et al. Major bloodstream infection-causing bacterial pathogens and their antimicrobial resistance in South Korea, 2017–2019: phase I report from kor-glass. Front Microbiol. 2021;12: 799084.

    Article  PubMed  Google Scholar 

  3. Prematunge C, MacDougall C, Johnstone J, Adomako K, Lam F, Robertson J, et al. Vre and vse bacteremia outcomes in the era of effective vre therapy: a systematic review and meta-analysis. Infect Control Hosp Epidemiol. 2016;37:26–35.

    Article  PubMed  Google Scholar 

  4. Alevizakos M, Gaitanidis A, Nasioudis D, Tori K, Flokas ME, Mylonakis E. Colonization with vancomycin-resistant enterococci and risk for bloodstream infection among patients with malignancy: a systematic review and meta-analysis. Open Forum Infect Dis. 2017;4: ofw246.

    Article  PubMed  Google Scholar 

  5. Carvalhaes CG, Sader HS, Streit JM, Castanheira M, Mendes RE. Activity of oritavancin against gram-positive pathogens causing bloodstream infections in the United States over 10 years: focus on drug-resistant enterococcal subsets (2010–2019). Antimicrob Agents Chemother. 2022;66: e0166721.

    Article  PubMed  Google Scholar 

  6. Freitas AR, Tedim AP, Francia MV, Jensen LB, Novais C, Peixe L, et al. Multilevel population genetic analysis of vana and vanb Enterococcus faecium causing nosocomial outbreaks in 27 countries (1986–2012). J Antimicrob Chemother. 2016;71:3351–66.

    Article  CAS  PubMed  Google Scholar 

  7. Arthur M, Molinas C, Depardieu F, Courvalin P. Characterization of tn1546, a tn3-related transposon conferring glycopeptide resistance by synthesis of depsipeptide peptidoglycan precursors in Enterococcus faecium bm4147. J Bacteriol. 1993;175:117–27.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Courvalin P. Vancomycin resistance in gram-positive cocci. Clin Infect Dis. 2006;42(Suppl 1):S25-34.

    Article  CAS  PubMed  Google Scholar 

  9. Dahl KH, Røkenes TP, Lundblad EW, Sundsfjord A. Nonconjugative transposition of the vanb-containing tn5382-like element in Enterococcus faecium. Antimicrob Agents Chemother. 2003;47:786–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Quintiliani R Jr, Courvalin P. Conjugal transfer of the vancomycin resistance determinant vanb between enterococci involves the movement of large genetic elements from chromosome to chromosome. FEMS Microbiol Lett. 1994;119:359–63.

    Article  CAS  PubMed  Google Scholar 

  11. Lee RS, Gonçalvesda Silva A, Baines SL, Strachan J, Ballard S, Carter GP, et al. The changing landscape of vancomycin-resistant Enterococcus faecium in Australia: a population-level genomic study. J Antimicrob Chemother. 2018;73:3268–78.

    CAS  PubMed  Google Scholar 

  12. van Hal SJ, Beukers AG, Timms VJ, Ellem JA, Taylor P, Maley MW, et al. Relentless spread and adaptation of non-typeable vana vancomycin-resistant Enterococcus faecium: a genome-wide investigation. J Antimicrob Chemother. 2018;73:1487–91.

    Article  PubMed  Google Scholar 

  13. Correa-Martínez CL, Jurke A, Schmitz J, Schaumburg F, Kampmeier S, Mellmann A. Molecular epidemiology of vancomycin-resistant enterococci bloodstream infections in Germany: a population-based prospective longitudinal study. Microorganisms. 2022;10.

  14. Kim HM, Chung DR, Cho SY, Huh K, Kang CI, Peck KR. Emergence of vancomycin-resistant Enterococcus faecium st1421 lacking the psts gene in Korea. Eur J Clin Microbiol Infect Dis. 2020;39:1349–56.

    Article  CAS  PubMed  Google Scholar 

  15. Vogwill T, MacLean RC. The genetic basis of the fitness costs of antimicrobial resistance: a meta-analysis approach. Evol Appl. 2015;8:284–95.

    Article  PubMed  Google Scholar 

  16. Rajer F, Sandegren L. The role of antibiotic resistance genes in the fitness cost of multiresistance plasmids. MBio. 2022;13:e0355221.

    Article  PubMed  Google Scholar 

  17. Lenski RE, Simpson SC, Nguyen TT. Genetic analysis of a plasmid-encoded, host genotype-specific enhancement of bacterial fitness. J Bacteriol. 1994;176:3140–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. San Millan A, Peña-Miller R, Toll-Riera M, Halbert ZV, McLean AR, Cooper BS, et al. Positive selection and compensatory adaptation interact to stabilize non-transmissible plasmids. Nat Commun. 2014;5:5208.

    Article  CAS  PubMed  Google Scholar 

  19. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.

    Article  CAS  PubMed  Google Scholar 

  20. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, et al. The sofa (sepsis-related organ failure assessment) score to describe organ dysfunction/failure. On behalf of the working group on sepsis-related problems of the European society of intensive care medicine. Intensive Care Med. 1996;22:707–10.

    Article  CAS  PubMed  Google Scholar 

  21. Clinical and Laboratory Standards Institute (CLSI) 2023. Performance Standards for Antimicrobial Susceptibility Testing. 33rd ed. CLSI supplement M100. Clinical and Laboratory Standards Institute, Wayne, PA.

  22. Elsayed S, Hamilton N, Boyd D, Mulvey M. Improved primer design for multiplex pcr analysis of vancomycin-resistant enterococcus spp. J Clin Microbiol. 2001;39:2367–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Teo JW, Krishnan P, Jureen R, Lin RT. Detection of an unusual van genotype in a vancomycin-resistant Enterococcus faecium hospital isolate. J Clin Microbiol. 2011;49:4297–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Prokka ST. Rapid prokaryotic genome annotation. Bioinformatics. 2014;30:2068–9.

    Article  Google Scholar 

  25. Homan WL, Tribe D, Poznanski S, Li M, Hogg G, Spalburg E, et al. Multilocus sequence typing scheme for Enterococcus faecium. J Clin Microbiol. 2002;40:1963–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. de Been M, Pinholt M, Top J, Bletz S, Mellmann A, van Schaik W, et al. Core genome multilocus sequence typing scheme for high- resolution typing of Enterococcus faecium. J Clin Microbiol. 2015;53:3788–97.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Bortolaia V, Kaas RS, Ruppe E, Roberts MC, Schwarz S, Cattoir V, et al. Resfinder 4.0 for predictions of phenotypes from genotypes. J Antimicrob Chemother. 2020;75:3491–500.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Carattoli A, Hasman H. Plasmidfinder and in silico pmlst: identification and typing of plasmid replicons in whole-genome sequencing (wgs). Methods Mol Biol. 2020;2075:285–94.

    Article  CAS  PubMed  Google Scholar 

  29. Makarova KS, Wolf YI, Koonin EV. Comprehensive comparative-genomic analysis of type 2 toxin-antitoxin systems and related mobile stress response systems in prokaryotes. Biol Direct. 2009;4:19.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Hashimoto Y, Tanimoto K, Ozawa Y, Murata T, Ike Y. Amino acid substitutions in the vans sensor of the vana-type vancomycin-resistant enterococcus strains result in high-level vancomycin resistance and low-level teicoplanin resistance. FEMS Microbiol Lett. 2000;185:247–54.

    Article  CAS  PubMed  Google Scholar 

  31. Schwarz FV, Perreten V, Teuber M. Sequence of the 50-kb conjugative multiresistance plasmid pre25 from enterococcus faecalis re25. Plasmid. 2001;46:170–87.

    Article  CAS  PubMed  Google Scholar 

  32. Hashimoto Y, Taniguchi M, Uesaka K, Nomura T, Hirakawa H, Tanimoto K, et al. Novel multidrug-resistant enterococcal mobile linear plasmid pelf1 encoding vana and vanm gene clusters from a Japanese vancomycin-resistant enterococci isolate. Front Microbiol. 2019;10:2568.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Arthur M, Depardieu F, Reynolds P, Courvalin P. Quantitative analysis of the metabolism of soluble cytoplasmic peptidoglycan precursors of glycopeptide-resistant enterococci. Mol Microbiol. 1996;21:33–44.

    Article  CAS  PubMed  Google Scholar 

  34. Thaker MN, Kalan L, Waglechner N, Eshaghi A, Patel SN, Poutanen S, et al. Vancomycin-variable enterococci can give rise to constitutive resistance during antibiotic therapy. Antimicrob Agents Chemother. 2015;59:1405–10.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Foucault ML, Depardieu F, Courvalin P, Grillot-Courvalin C. Inducible expression eliminates the fitness cost of vancomycin resistance in enterococci. Proc Natl Acad Sci U S A. 2010;107:16964–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Dahlberg C, Chao L. Amelioration of the cost of conjugative plasmid carriage in Eschericha coli k12. Genetics. 2003;165:1641–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Porse A, Schønning K, Munck C, Sommer MO. Survival and evolution of a large multidrug resistance plasmid in new clinical bacterial hosts. Mol Biol Evol. 2016;33:2860–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Tansirichaiya S, Goodman RN, Guo X, Bulgasim I, Samuelsen Ø, Al-Haroni M, et al. Intracellular transposition and capture of mobile genetic elements following intercellular conjugation of multidrug resistance conjugative plasmids from clinical enterobacteriaceae isolates. Microbiol Spectr. 2022;10: e0214021.

    Article  PubMed  Google Scholar 

  39. Yoon EJ, Gwon B, Liu C, Kim D, Won D, Park SG, et al. Beneficial chromosomal integration of the genes for ctx-m extended-spectrum β-lactamase in Klebsiella pneumoniae for stable propagation. mSystems. 2020;5.

  40. Yoon EJ, Kim JO, Yang JW, Kim HS, Lee KJ, Jeong SH, et al. The blaoxa-23-associated transposons in the genome of acinetobacter spp. Represent an epidemiological situation of the species encountering carbapenems. J Antimicrob Chemother. 2017;72:2708–14.

    Article  CAS  PubMed  Google Scholar 

  41. Fabre L, Delauné A, Espié E, Nygard K, Pardos de la Gandara M, Polomack L, et al. Chromosomal integration of the extended-spectrum beta-lactamase gene blactx-m-15 in salmonella enterica serotype concord isolates from internationally adopted children. Antimicrob Agents Chemother. 2009;53:1808–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Carter GP, Buultjens AH, Ballard SA, Baines SL, Tomita T, Strachan J, et al. Emergence of endemic mlst non-typeable vancomycin-resistant Enterococcus faecium. J Antimicrob Chemother. 2016;71:3367–71.

    Article  CAS  PubMed  Google Scholar 

  43. Song JH, Ko KS, Suh JY, Oh WS, Kang CI, Chung DR, et al. Clinical implications of vancomycin-resistant Enterococcus faecium (vre) with vand phenotype and vana genotype. J Antimicrob Chemother. 2008;61:838–44.

    Article  CAS  PubMed  Google Scholar 

  44. Naas T, Fortineau N, Snanoudj R, Spicq C, Durrbach A, Nordmann P. First nosocomial outbreak of vancomycin-resistant Enterococcus faecium expressing a vand-like phenotype associated with a vana genotype. J Clin Microbiol. 2005;43:3642–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

This research was supported by the Korea Disease Control and Prevention Agency (2017E4400102, 2023-10-001, 2023-10-002).

Author information

Authors and Affiliations

  1. Department of Laboratory Medicine and Research Institute of Bacterial Resistance, Gangnam Severance Hospita, l, Yonsei University College of Medicine, 211 Eonju-Ro, Gangnam-Gu, Seoul, 06273, South Korea

    Dokyun Kim, Da Young Kang, Min Hyuk Choi, Jun Sung Hong & Seok Hoon Jeong

  2. Department of Companion Animal Health and Science, Silla University, Busan, South Korea

    Jun Sung Hong

  3. Department of Laboratory Medicine, Hallym University Dongtan Sacred Heart Hospital, Hallym University College of Medicine, Hwaseong, South Korea

    Hyun Soo Kim

  4. Department of Laboratory Medicine, Jeju National University College of Medicine, Jeju, South Korea

    Young Ree Kim

  5. Department of Laboratory Medicine, National Health Insurance Service, Ilsan Hospital, Goyang, South Korea

    Young Ah Kim

  6. Department of Laboratory Medicine, Yonsei University Wonju College of Medicine, Wonju, South Korea

    Young Uh

  7. Department of Laboratory Medicine, Chungbuk National University College of Medicine, Cheongju, South Korea

    Kyeong Seob Shin

  8. Department of Laboratory Medicine and Paik Institute for Clinical Research, Inje University College of Medicine, Busan, South Korea

    Jeong Hwan Shin

  9. Department of Laboratory Medicine, Chonnam National University Medical School, Gwangju, South Korea

    Soo Hyun Kim & Jong Hee Shin

Authors
  1. Dokyun Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Da Young Kang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Min Hyuk Choi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jun Sung Hong
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hyun Soo Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Young Ree Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Young Ah Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Young Uh
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Kyeong Seob Shin
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Jeong Hwan Shin
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Soo Hyun Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Jong Hee Shin
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Seok Hoon Jeong
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Conceptualization (D.K., S.H.J.); Collection of clinical data and bacterial isolates (M.H.C., J.S.H., H.S.K., Y.R.K., Y.A.K, Y.U., K.S.S., J.H.S.7, S.H.K., J.H.S.8); Bacterial experiments (D.Y.K., J.S.H.); Statistical analysis and visualization (D.K.); Interpretation of data (D.K., S.H.J.); Writing-original draft (D.K., S.H.J.); Critical reading (all authors); Writing-review and editing (D.K., S.H.J.); Funding acquisition (D.K., S.H.K., S.H.J.)

Corresponding author

Correspondence to Seok Hoon Jeong.

Ethics declarations

Ethics approval and consent to participate

The requirement for an informed consent from the participants was waived by all local institutional review boards of the hospitals, including Gangnam Severance Hospital, National Health Insurance Service Ilsan Hospital, Wonju Severance Christian Hospital, Chungbuk National University Hospital, Chonnam National University Hospital, Busan Paik Hospital, Dongtan Sacred Heart Hospital, and Jeju National University Hospital.

Competing interests

None to declare.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kim, D., Kang, D.Y., Choi, M.H. et al. Fitness costs of Tn1546-type transposons harboring the vanA operon by plasmid type and structural diversity in Enterococcus faecium. Ann Clin Microbiol Antimicrob 23, 62 (2024). https://doi.org/10.1186/s12941-024-00722-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12941-024-00722-2

Keywords

Annals of Clinical Microbiology and Antimicrobials

ISSN: 1476-0711

Contact us